Literature DB >> 11717153

Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes.

G G Neri Serneri1, M Boddi, P A Modesti, I Cecioni, M Coppo, L Padeletti, A Michelucci, A Colella, G Galanti.   

Abstract

Physiological hypertrophy represents the adaptive changes of the heart required for supporting the increased hemodynamic load in regularly trained healthy subjects. Mechanisms responsible for the athlete's hypertrophy still remain unknown. In 15 trained competitive soccer players and in 15 healthy men not engaged in sporting activities (sedentary control subjects) of equivalent age, we investigated the relationship among cardiac growth factor formation, cardiac sympathetic activity, and left ventricular morphology and function. Cardiac formation of insulin-like growth factor (IGF)-I, endothelin (ET)-1, big ET-1, and angiotensin (Ang) II was investigated at rest by measuring artery-coronary sinus concentration gradients. Cardiac sympathetic activity was studied by [(3)H]norepinephrine (NE) kinetics. Cardiac IGF-I, but not ET-1, big ET-1, and Ang II, formation was higher in athletes than in control subjects (P<0.01). NE levels in arterial and peripheral venous blood did not differ between groups. In contrast, coronary sinus NE concentration was higher in athletes than in control subjects (P<0.01). Cardiac, but not total systemic, NE spillover was also increased in athletes (P<0.01), whereas cardiac [(3)H]NE reuptake and clearance were not different. Echocardiographic modifications indicated a volume overload-induced hypertrophy associated with increased myocardial contractility. Multivariate stepwise analysis selected left ventricular mass index as the most predictive independent variable for cardiac IGF-I formation and velocity of circumferential fiber shortening for cardiac NE spillover. In conclusion, increased cardiac IGF-I formation and enhanced sympathetic activity selectively confined to the heart appear to be responsible for the physiological hypertrophy in athletes performing predominantly isotonic exercise.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11717153     DOI: 10.1161/hh2301.100982

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  51 in total

1.  Resveratrol prevents pathological but not physiological cardiac hypertrophy.

Authors:  Vernon W Dolinsky; Carrie-Lynn M Soltys; Kyle J Rogan; Anita Y M Chan; Jeevan Nagendran; Shaohua Wang; Jason R B Dyck
Journal:  J Mol Med (Berl)       Date:  2014-11-15       Impact factor: 4.599

Review 2.  Electrical and mechanical stimulation of cardiac cells and tissue constructs.

Authors:  Whitney L Stoppel; David L Kaplan; Lauren D Black
Journal:  Adv Drug Deliv Rev       Date:  2015-07-30       Impact factor: 15.470

Review 3.  Influence of Physical Activity on Hypertension and Cardiac Structure and Function.

Authors:  Sheila M Hegde; Scott D Solomon
Journal:  Curr Hypertens Rep       Date:  2015-10       Impact factor: 5.369

Review 4.  Cardiovascular Adaptations Induced by Resistance Training in Animal Models.

Authors:  S F S Melo; N D da Silva Júnior; V G Barauna; E M Oliveira
Journal:  Int J Med Sci       Date:  2018-02-12       Impact factor: 3.738

5.  Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy.

Authors:  Julie R McMullen; Fatemeh Amirahmadi; Elizabeth A Woodcock; Martina Schinke-Braun; Russell D Bouwman; Kimberly A Hewitt; Janelle P Mollica; Li Zhang; Yunyu Zhang; Tetsuo Shioi; Antje Buerger; Seigo Izumo; Patrick Y Jay; Garry L Jennings
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-03       Impact factor: 11.205

6.  Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy.

Authors:  Jaetaek Kim; Adam R Wende; Sandra Sena; Heather A Theobald; Jamie Soto; Crystal Sloan; Benjamin E Wayment; Sheldon E Litwin; Martin Holzenberger; Derek LeRoith; E Dale Abel
Journal:  Mol Endocrinol       Date:  2008-09-18

7.  Peroxisome proliferator-activated receptor-γ coactivator 1 α1 induces a cardiac excitation-contraction coupling phenotype without metabolic remodelling.

Authors:  Maija Mutikainen; Tomi Tuomainen; Nikolay Naumenko; Jenni Huusko; Boris Smirin; Svetlana Laidinen; Krista Kokki; Heidi Hynynen; Seppo Ylä-Herttuala; Merja Heinäniemi; Jorge L Ruas; Pasi Tavi
Journal:  J Physiol       Date:  2016-12-01       Impact factor: 5.182

Review 8.  Molecular basis of physiological heart growth: fundamental concepts and new players.

Authors:  Marjorie Maillet; Jop H van Berlo; Jeffery D Molkentin
Journal:  Nat Rev Mol Cell Biol       Date:  2013-01       Impact factor: 94.444

Review 9.  Exercise and gene expression: physiological regulation of the human genome through physical activity.

Authors:  Frank W Booth; Manu V Chakravarthy; Espen E Spangenburg
Journal:  J Physiol       Date:  2002-09-01       Impact factor: 5.182

10.  Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy.

Authors:  Karina Huynh; Julie R McMullen; Tracey L Julius; Joon Win Tan; Jane E Love; Nelly Cemerlang; Helen Kiriazis; Xiao-Jun Du; Rebecca H Ritchie
Journal:  Diabetes       Date:  2010-03-09       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.